James A. Fagin
Affiliations: | University of Cincinnati, Cincinnati, OH |
Area:
Animal Physiology Biology, Cell BiologyGoogle:
"James Fagin"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Fagin JA, Nikiforov YE. (2023) Progress in Thyroid Cancer Genomics: A 40-Year Journey. Thyroid : Official Journal of the American Thyroid Association |
| Landa I, Thornton CE, Xu B, et al. (2023) Telomerase upregulation induces progression of mouse BrafV600E-driven thyroid cancers and triggers non-telomeric effects. Molecular Cancer Research : McR |
| Fagin JA, Krishnamoorthy GP, Landa I. (2023) Pathogenesis of cancers derived from thyroid follicular cells. Nature Reviews. Cancer |
| Landa I, Thornton CE, Xu B, et al. (2023) Telomerase reactivation induces progression of mouse Braf -driven thyroid cancers without telomere lengthening. Biorxiv : the Preprint Server For Biology |
| Spourquet C, Delcorte O, Lemoine P, et al. (2022) BRAF Expression in Thyrocytes Causes Recruitment of Immunosuppressive STABILIN-1 Macrophages. Cancers. 14 |
| Boucai L, Salas-Lucia F, Krishnamoorthy GP, et al. (2022) Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase. Jco Precision Oncology. 6: e2100496 |
| Tchekmedyian V, Dunn L, Sherman EJ, et al. (2022) Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial. Thyroid : Official Journal of the American Thyroid Association |
| Boucai L, Seshan V, Williams M, et al. (2021) Characterization of Subtypes of BRAF-Mutant Papillary Thyroid Cancer Defined by Their Thyroid Differentiation Score. The Journal of Clinical Endocrinology and Metabolism |
| Lee M, Untch BR, Xu B, et al. (2021) Genomic and transcriptomic correlates of thyroid carcinoma evolution after BRAF inhibitor therapy. Molecular Cancer Research : McR |
| Luckett KA, Cracchiolo JR, Krishnamoorthy GP, et al. (2021) Co-inhibition of SMAD and MAPK signaling enhances 124I update in BRAF-mutant thyroid cancers. Endocrine-Related Cancer |